胶质瘤
药物输送
细胞外小泡
医学
临床试验
药品
神经科学
纳米技术
药理学
癌症研究
心理学
病理
材料科学
生物
细胞生物学
作者
Jiwei Cui,Yuanxin Xu,Haiyan Tu,Huacong Zhao,Honglan Wang,Liuqing Di,Ruoning Wang
标识
DOI:10.1016/j.apsb.2021.08.013
摘要
Due to the special physiological and pathological characteristics of gliomas, most therapeutic drugs are prevented from entering the brain. To improve the poor prognosis of existing therapies, researchers have been continuously developing non-invasive methods to overcome barriers to gliomas therapy. Although these strategies can be used clinically to overcome the blood‒brain barrier (BBB), the accurate delivery of drugs to the glioma lesions cannot be ensured. Nano-drug delivery systems (NDDS) have been widely used for precise drug delivery. In recent years, researchers have gathered their wisdom to overcome barriers, so many well-designed NDDS have performed prominently in preclinical studies. These meticulous designs mainly include cascade passing through BBB and targeting to glioma lesions, drug release in response to the glioma microenvironment, biomimetic delivery systems based on endogenous cells/extracellular vesicles/protein, and carriers created according to the active ingredients of traditional Chinese medicines. We reviewed these well-designed NDDS in detail. Furthermore, we discussed the current ongoing and completed clinical trials of NDDS for gliomas therapy, and analyzed the challenges and trends faced by clinical translation of these well-designed NDDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI